Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2009

View Archived Issues

Mitsubishi Tanabe obtains approval in Japan for changes to Remicade in RA

Specifid does not improve progression-free survival in follicular lymphoma

Nasal Pseudomonas aeruginosa vaccine evaluated in chronic lung disease patients

Argenta Discovery identifies novel HNE inhibitors

GlaxoSmithKline claims soluble epoxide hydrolase inhibitors

Takeda describes tachykinin receptor antagonists

Filgrastim shows promise in Alzheimer's disease model, clinical trial planned

Recent study suggests pregabalin may be a possible treatment for refractory bipolar disorder

Oxcarbazepine beneficial when added to lithium for bipolar I and II disorders

Clodronate reduces disease severity in model of Guillain-Barre syndrome

Treague and MMV initiate phase I clinical trial of (+)-mefloquine for malaria

Repros and NIH amend license agreement for Proellex

Amgen reports results from phase III trial of denosumab vs. Zometa in advanced breast cancer

FDA accepts Silenor NDA; Somaxon initiates private equity financing

Procter & Gamble launches Asacol HD for active ulcerative colitis in the U.S.

Safety Evaluation Committee approves advancement of iCo's phase I clinical trial of iCo-007

Array BioPharma reports top-line results from two phase I ARRY-797 trials

AstraZeneca will advance AZD-3480 program in ADHD

Encapsulated choroid plexus cells could have potential in treating hearing loss

Lumigan approved in Japan for glaucoma/ocular hypertension

Biogen receives FDA fast track designation for PEGylated interferon beta-1a

Vical reports 4-month interim results from phase II trial of TransVax CMV vaccine

Amylin reports results from phase II of pramlintide/metreleptin combination treatment in obesity

Rigel reports results from phase IIb TASKi2 clinical trial of R-788 in RA patients

Cangene acquires all issued and outstanding shares of Twinstrand